| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 653.2 | 629.2 | 603.0 |
| Other income | 44.8 | 40.7 | 67.2 |
| Total income | 698.0 | 670.0 | 670.2 |
| Profit before exceptional items & tax | 276.7 | 259.8 | 259.5 |
| Exceptional items | 0.0 | 9.0 | 0.0 |
| Profit before tax | 276.7 | 268.8 | 259.5 |
| Net profit | 204.5 | 199.8 | 191.8 |
| Operating margin | 39.6% | 40.1% | 38.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +6.60% |
|---|---|
| Net profit, quarter on quarter | +2.40% |
| Revenue, year on year | +8.30% |
| Operating profit, year on year | +28.20% |
| Operating profit, quarter on quarter | +0.40% |
BSE results filing, NSE: PFIZER. Figures extracted from the filing.
Pfizer Ltd: key numbers
- Share price
- ₹4,000.80
- Market cap
- ₹18,303 Cr
- Revenue (annual)
- ₹2,520 Cr
- Net profit (annual)
- ₹722.4 Cr
- P/E (TTM)
- 24.9×Sector 50.4×
- Promoter holding
- 63.92%+0.00% QoQ
- FII holding
- 1.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pfizer Ltd
All →Pfizer Management Change
Pfizer Limited announced the resignation of Mr. Sharad Goswami, Senior Director – Policy & Public Affairs, effective from the close of business on September 25, 2026.
Pfizer Board Meeting Outcome
Pfizer Board approved discontinuation of Minipress XL effective September 7, 2026. The company will receive ₹131.38 Crore lump-sum payment from Pfizer Inc., USA.
- Value
- ₹131.4 Cr
Pfizer Q4 FY26 Results: Net Profit ₹199.8 Cr, Down 39.6% YoY
Pfizer Ltd reported revenue from operations of ₹629.2 Cr (+6.3% YoY) and net profit of ₹199.8 Cr (-39.6% YoY) for Q4 FY26.
- Key figure
- Net profit ₹199.8 Cr · -39.6% YoY